Vilaprisan (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name) (developmental code name BAY-1002670) is a synthetic and steroidal selective progesterone receptor modulator (SPRM) which is under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis and uterine fibroids.

[1][2][3] It is a potent and highly selective partial agonist of the progesterone receptor (PR).

[4][2][3] As of 2017, the drug is in phase II clinical trials for the aforementioned indications.

This article about a steroid is a stub.

You can help Wikipedia by expanding it.This drug article relating to the genito-urinary system is a stub.